Immunotherapy-related skin toxicity: Bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab

European Journal of Dermatology

Volumn 27, Issue 2, 2017, Pages 205-208

  Russo, Irene ^a   Sacco, Giorgia ^a   Frega, Stefano ^b   Polo, Valentina ^b   Pasello, Giulia ^b   Alaibac, Mauro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; CETIRIZINE; CISPLATIN; CLOBETASOL PROPIONATE; DOXYCYCLINE; GEMCITABINE; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; SKIN CREAM; TETRACYCLINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; BULLOUS PEMPHIGOID; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LETTER; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRURITUS; RASH; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; ADENOCARCINOMA; CHEMICALLY INDUCED; IMMUNOTHERAPY; LUNG TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS;

EID: 85017628853     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2016.2959     Document Type: Letter

References (10)

1. Jing W, Li M, Zhang Y, et al. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016; 9: 489-502.
2. Seetharamu N, Budman DR, Sullivan KM. Immune checkpoint inhibitors in lung cancer: past, present and future. Future Oncol 2016; 12: 151-63.
3. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4: 383-9.
4. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190-209.
5. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 2016; 43: 688-96.
6. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015; 25: 265-8.
7. Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with antiprogrammed cell death 1 antibodies. Melanoma Res 2016; 26: 413-6.
8. Parakh S, Nguyen R, Opie JM, Andrews MC. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J Dermatol 2016, May 11. doi: 10.1111/ajd.12488. [Epub ahead of print].
9. Büdinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998; 102: 2082-9.
10. Krenacs T, Kiszner G, Stelkovics E, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol 2012; 138: 653-67.